ObsEva S.A. (OBSN.SW) closed at CHF 0.0012 on 10 Mar 2026 as markets closed on SIX, posting a -76.92% intraday move and heavy volume. The dramatic drop made OBSN.SW stock one of the most active names on the Swiss exchange, trading 2,351,202 shares versus an average of 675,842. Traders and analysts are watching liquidity, clinical catalysts, and cash runway. Meyka AI monitored the session and flagged the spike for follow-up market analysis.
OBSN.SW stock trading activity and market facts
OBSN.SW stock showed a wide intraday spread, opening at CHF 0.0050, hitting a day high of CHF 0.0058 and a day low of CHF 0.0012. Volume reached 2,351,202 shares, a relative volume of 3.48, indicating outsized interest compared with the average volume of 675,842. The market cap sits near CHF 140,612.00, reflecting the low share price and 117,177,000 shares outstanding.
OBSN.SW stock fundamentals and financials
ObsEva operates in Healthcare, specifically Biotechnology, with core programs including linzagolix and ebopiprant. Latest reported EPS is -0.29 and price-earnings is negative. Balance-sheet metrics show cash per share 0.0915 and a current ratio of 2.23, signalling short-term liquidity that can support near-term operations. Revenue per share TTM is 0.2133, but net income per share is negative at -0.3245.
OBSN.SW stock technical and relative trends
The 50-day average price is CHF 0.01469 and the 200-day average is CHF 0.04393, both well above the closing price, underlining severe downtrend pressure. Year high sits at CHF 0.0850 and year low at CHF 0.0012, so price is near its annual low. These technicals show heavy long-term erosion and elevated volatility for short-term traders.
Meyka AI rates OBSN.SW with a score out of 100
Meyka AI rates OBSN.SW with a score of 62.66 out of 100, grade B, suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, industry comparison, financial growth, key metrics, and analyst consensus. The grade reflects weak price momentum but some fundamental liquidity and clinical pipeline value. These grades are informational only and are not financial advice.
OBSN.SW stock valuation, price targets and Meyka forecast
Market consensus price targets are not established. Meyka AI’s forecast model projects a 12-month base target of CHF 0.0050, a conservative target of CHF 0.0025, and a bull target of CHF 0.0100. Versus the current price of CHF 0.0012, the base target implies an upside of +316.67%, the conservative target implies +108.33%, and the bull target implies +733.33%. Forecasts are model-based projections and not guarantees.
OBSN.SW stock risks and sector context
Key risks include clinical trial outcomes, financing needs, and high dilution risk given the low share price. ObsEva operates within Healthcare where the average PE is 30.19 and the sector showed -1.05% on the day, making OBSN.SW an outlier in both volatility and downside. For liquidity checks, use official market data on SIX Exchange.
Final Thoughts
OBSN.SW stock closed at CHF 0.0012 on 10 Mar 2026 after a large intraday fall and heavy volume. The session placed ObsEva among the most active names on SIX, with volume 2,351,202 and rel volume 3.48. Fundamentals show negative EPS -0.29 and a thin market cap near CHF 140,612.00, suggesting the price reflects both clinical and funding risk. Meyka AI’s forecast model projects a 12-month base target of CHF 0.0050, implying a +316.67% move from the close; conservative and bull scenarios sit at CHF 0.0025 (+108.33%) and CHF 0.0100 (+733.33%). These projections are model-based and not guarantees. Traders should weigh clinical timelines, dilution risk, and the company’s cash per share 0.0915 before acting. For company detail and filings visit the ObsEva site at ObsEva. Our view: high-volatility, catalyst-driven opportunity for informed, risk-tolerant investors rather than a broad-market pick.
FAQs
What drove the big move in OBSN.SW stock today?
The sharp move was driven by heavy intraday volume of 2,351,202 shares and a steep price fall to CHF 0.0012. Catalyst risk, trading liquidity and positioning around clinical updates likely amplified the move. OBSN.SW stock reacts strongly to clinical and financing news.
What valuation metrics should investors watch for OBSN.SW stock?
Focus on cash per share (0.0915), current ratio (2.23), EPS (-0.29) and shares outstanding (117,177,000). These metrics show liquidity and dilution risk that matter more than standard PE multiples for OBSN.SW stock.
Does Meyka AI provide a price forecast for OBSN.SW stock?
Yes. Meyka AI’s forecast model projects a 12-month base target of CHF 0.0050, implying +316.67% from CHF 0.0012. Forecasts are model outputs and not guarantees. Use them with clinical and financing risk analysis.
Is OBSN.SW stock suitable for long-term investors?
OBSN.SW stock is high risk for long-term portfolios due to negative earnings, pipeline dependency, and dilution risk. Long-term suitability depends on conviction in ObsEva’s clinical programs and ability to finance operations.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)